The 2nd European Carotid Surgery Trial (ECST-2): rationale and protocol for a randomised clinical trial comparing immediate revascularisation versus optimised medical therapy alone in patients with symptomatic and asymptomatic carotid stenosis at low to intermediate risk of stroke

Suk Fun Cheng1, Twan J. van Velzen2, John Gregson3, Toby Richards4, Hans Rolf Jäger5,6, Robert Simister1,7, M. Eline Kooi8, Gert J. de Borst9, Francesca B. Pizzini10, Paul J. Nederkoorn2†, Martin M. Brown1‡, and Leo H. Bonati11,12,13†

Abstract

Background: Carotid endarterectomy is currently recommended for patients with recently symptomatic carotid stenosis ≥50%, based on randomised trials conducted 30 years ago. Several factors such as carotid plaque ulceration, age and associated comorbidities might influence the risk-benefit ratio of carotid revascularisation. A model developed in previous trials that calculates the future risk of stroke based on these features can be used to stratify patients into low, intermediate or high risk. Since the original trials, medical treatment has improved significantly. Our hypothesis is that patients with carotid stenosis ≥50% associated with a low to intermediate risk of stroke will not benefit from additional carotid revascularisation when treated with optimised medical therapy. We also hypothesise that prediction of future risk of stroke in individual patients with carotid stenosis can be improved using the results of magnetic resonance imaging (MRI) of the carotid plaque.

Methods: Patients are randomised between immediate revascularisation plus OMT versus OMT alone. Suitable patients are those with asymptomatic or symptomatic carotid stenosis ≥50% with an estimated 5-year risk of stroke of <20%, as calculated using the Carotid Artery Risk score. MRI of the brain at baseline and during follow-up will be used as a blinded measure to assess the incidence of silent infarction and haemorrhage, while carotid plaque MRI

†Paul J. Nederkoorn, Martin M. Brown and Leo H. Bonati contributed equally to this work.

*Correspondence: martin.brown@ucl.ac.uk

1 Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
at baseline will be used to investigate the hypotheses that plaque characteristics determine future stroke risk and help identify a subgroup of patients that will benefit from revascularisation. An initial analysis will be conducted after recruitment of 320 patients with baseline MRI and a minimum of 2 years of follow-up, to provide data to inform the design and sample size for a continuation or re-launch of the study. The primary outcome measure of this initial analysis is the combined 2-year rate of any clinically manifest stroke, new cerebral infarct on MRI, myocardial infarction or periprocedural death.

Discussion: ECST-2 will provide new data on the efficacy of modern optimal medical therapy alone versus added carotid revascularisation in patients with carotid stenosis at low to intermediate risk of future stroke selected by individualised risk assessment. We anticipate that the results of baseline brain and carotid plaque MRI will provide data to improve the prediction of the risk of stroke and the effect of treatment in patients with carotid stenosis.

Trial registration: ISRCTN registry ISRCTN97744893. Registered on 05 July 2012

Keywords: Carotid stenosis, Ischaemic stroke, Carotid endarterectomy, Carotid stenting, Risk prediction, Magnetic resonance imaging, Plaque imaging, Randomised controlled trial

Introduction

Background and rationale (6a)
Atherosclerotic stenosis at or around the carotid bifurcation is associated with an increased risk of ischaemic stroke in the ipsilateral carotid artery territory and accounts for 10–20% of all transient ischaemic attacks (TIA) and ischaemic strokes [1]. The first European Carotid Surgery Trial (ECST) and the North American Carotid Endarterectomy Trial (NASCET) both showed a benefit of carotid endarterectomy (CEA) in preventing stroke in patients with symptomatic stenosis of $\geq 70\%$ [2, 3]. These trials show that CEA carried a perioperative risk of stroke and death of around 7%. Moreover, CEA did not prevent all recurrent strokes. NASCET did not show any benefit of CEA in patients with $<50\%$ stenosis, but there was a small benefit in those with $50–69\%$ stenosis [3]. The focus of guidelines based on ECST and NASCET has been to recommend CEA on the basis of the degree of carotid stenosis and this has dictated clinical practice to date. However, analysis of individual data from both these trials has shown that multiple factors in addition to the degree of stenosis, such as age, sex, time from index event, carotid plaque morphology and patient comorbidities, influenced the risk of future stroke in patients treated with medical therapy alone and also the amount of risk reduction through CEA [4].

A risk model based on these factors, derived from ECST and validated in NASCET showed that in patients with symptomatic carotid stenosis, the risk of ipsilateral stroke on medical therapy could be accurately predicted...
from baseline characteristics. It was evident from this analysis that only patients with a high risk of subsequent ipsilateral stroke when treated medically benefitted from CEA, while patients with a lower risk of stroke (5-year risk of <20%) did not benefit significantly because the benefit of surgery in the longer-term prevention of stroke did not justify the perioperative risk of stroke or death (Fig. 1) [4, 5].

In the Asymptomatic Carotid Surgery Trial (ACST), 3120 patients with asymptomatic carotid stenosis were randomised between immediate and deferred CEA [6, 7]. This trial did not include a fixed minimum stenosis percentage. The results of this trial showed a benefit of CEA in patients younger than 75 years of age with ≥60% carotid stenosis [6, 7]. Immediate CEA halved the 5-year stroke risk from 12 to 6% in these patients but the absolute risks were low (13.4% vs. 17.9%) with a net gain over 10 years of only 4.6% (95% CI 1.2–7.9). The median delay in this group was 1 month. The Asymptomatic Carotid Atherosclerosis Study (ACAS) showed a similar reduction in risk among patients with asymptomatic carotid stenosis ≥60% who received CEA versus medical therapy alone [8]. ACAS showed a 5-year stroke risk of 11.0% in the medical group compared to 5.1% in the surgical group with a relative reduction of stroke risk of 53% (95% CI 22–72). Carotid artery stenting (CAS) has emerged as an alternative method to revascularise carotid stenosis, but randomised trials in symptomatic patients suggested that the early risks of CAS outweigh those of CEA, except in patients younger than 70 years of age [9–11].

Previous trials of CEA versus medical therapy assessed only clinically manifest stroke reported by the patient and confirmed by adjudication in line with the definition of stroke as symptoms likely to be of cerebrovascular origin lasting at least 24 h. However, brain magnetic resonance imaging (MRI) is much more sensitive than clinical assessment in detecting ischaemic brain infarcts. Silent brain infarcts on MRI were found in 8% of participants in the Rotterdam study [12] and developed in 20% of participants after 10 years of follow-up in the Atherosclerosis Risk in Communities Brain Magnetic Resonance Imaging Study [13]. Silent infarcts on MRI are also seen after revascularisation procedures [14–17]. MRI can detect cerebral infarcts in the absence of clinical signs and symptoms and approximately doubles the number of episodes of cerebral infarction (clinically manifest and silent stroke) detected during follow-up. Thus, incorporation of new infarcts on brain MRI as an outcome measure is more sensitive than clinical assessment and therefore reduces the sample size required to demonstrate significant differences in the outcome between the two treatments. Another advantage of using MRI to assess outcome after stroke is that the determination of outcome is more objective than clinical assessment and outcome assessment can be done independently and blind to treatment and patient characteristics, unlike clinical assessment.

Furthermore, MRI is able to detect structural features of plaque instability, such as intra-plaque haemorrhage (IPH), which may improve the identification

Fig. 1 Figure showing reliability of a predictive model of 5-year risk of ipsilateral stroke derived from ECST data validated using results observed in NASCET. The figure is adapted from Rothwell et al., [4] [with the addition of arrows to show the 5-year risk of stroke in CEA patients]
of patients benefiting from carotid revascularisation. The presence of IPH increases the risk of stroke in patients with carotid stenosis by a factor of more than ten and predicts risk independently of the degree of stenosis [18].

These considerations argued for a new trial to investigate the role of revascularisation in the setting of improved medical therapy adjusted to targets for risk factor control, i.e. optimised medical therapy (OMT), and using brain MRI to determine outcome measures. We therefore organised the Second European Carotid Surgery Trial (ECST-2).

Objectives [7]
The objective of ECST-2 is to investigate the hypothesis that patients with carotid stenosis ≥50% associated with a low to intermediate risk of stroke will not benefit from additional carotid revascularisation when treated with optimised medical therapy. We also aim to investigate the hypothesis that the findings on baseline carotid plaque imaging can be used to predict future stroke risk and identify a subgroup of patients that will benefit from carotid revascularisation.

Trial design [8]
ECST-2 is designed as a multicentre, prospective, randomised, controlled, open, multi-centre, non-inferiority clinical trial with blinded outcome adjudication of the primary outcome and 1:1 allocation to the two treatment arms balanced by minimisation.

Methods: participants, interventions, and outcomes
Study setting [9]
Participating centre requirements
Each centre is required to have a neurologist or physician with expertise in stroke to see patients prior to randomisation and to supervise follow-up and also a multidisciplinary process for ensuring that the management of individual patients with carotid stenosis is routinely discussed between physicians, surgeons, and radiologists. Centres are required to submit documentation demonstrating the training and experience of their investigators, together with an audit of the outcomes of carotid revascularisation at their centre. An expert credentialing committee is responsible for approving individual investigators and centre enrolment on the basis of acceptable outcomes from CEA, and also CAS if offered by the centre.

Thirty enrolled centres recruited and follow-up patients in the UK, Switzerland, the Netherlands, France, Germany, Italy and Canada. A list of the recruiting centres is available on the trial website (www.ecst2.com).

Eligibility criteria [10]
The inclusion and main exclusion criteria for the trial are summarised in Table 1.

Use of the Carotid Artery Risk (CAR) score
Patients with asymptomatic or symptomatic carotid stenosis ≥50% with an estimated 5-year risk of stroke of <20% are identified by centres as suitable for inclusion in ECST-2 using the Carotid Artery Risk (CAR) score. The CAR score predicts the 5-year risk of ipsilateral stroke on the side of the stenotic carotid artery in patients treated with optimised medical therapy alone. The score was originally derived from the results of a Cox regression model using data from patients who had been randomised to medical treatment in the first ECST and was independently validated in the NASCET trial [2–5, 19]. This showed that the model produced accurate predictions of future risk of stroke on best medical therapy alone. Those with a high risk of stroke on medical therapy alone did not have any increase in their risk of perioperative stroke from carotid endarterectomy. The model has been widely used in routine clinical practice to select patients for carotid endarterectomy, both in its full web-based form published as the Carotid Stenosis Risk Prediction Tool by the Stroke Prevention Unit at the University of Oxford and in the form of the risk tables derived from the model [4]. However, given the evidence that the risks of stroke under medical therapy have declined since the time of ECST and NASCET, we recalibrated the model for use in ECST-2, taking into account the published effects of modern medical treatment of carotid stenosis and some additional risk data provided by the Stroke Prevention Unit. We named the output of the recalibrated model the Carotid Artery Risk (CAR) score. The CAR score is calculated based on the following patient characteristics: sex, age, diabetes, myocardial infarction, peripheral vascular disease, hypertension, percentage of carotid stenosis, the presence of a near carotid occlusion, plaque ulceration, time in days from the last ischaemic event to expected day of randomisation, and type of event (major stroke/multiple or single TIA/monocular event). These factors are used to provide an individualised estimate of the patient's 5-year risk of ipsilateral stroke when treated with OMT alone. A tool is available on-line and as an app for use on smartphones and mobile devices to facilitate calculation of the CAR score in patients being considered for ECST-2.

The CAR score is used to select recently symptomatic patients at low or intermediate risk of stroke, which is defined as a 5-year risk of stroke ipsilateral to...
Inclusion criteria
- Patients over 18 years of age
- Symptomatic or asymptomatic atherosclerotic carotid stenosis of at least 50% calculated using the NASCET criteria
- Patients with a CAR score indicating a 5-year ipsilateral stroke risk of <20%
- Patient is medically and neurologically stable and suitable for either CEA or CAS
- Clinicians are uncertain about which treatment modality (OMT or OMT plus revascularisation) is best for the individual patient
- Patient is able and willing to give informed consent

Exclusion criteria
- Patients with a modified Rankin score (mRS) > 2
- Patients who are medically or neurologically unstable
- Patients who have had coronary artery bypass grafting within 3 months or other major surgery within 6 weeks prior to randomisation
- Patients with a CAR Score ≥20%
- Occlusion of the carotid artery considered for randomisation
- Patients not suitable for either surgery or stenting due to anatomical factors
- Intraluminal thrombus within the carotid seen on ultrasound or angiography
- Carotid stenosis caused by non-atherosclerotic disease, e.g. dissection, fibromuscular disease or neck radiotherapy
- Previous CEA or CAS in the artery to be randomised
- Recent revascularisation of the contralateral carotid artery or a vertebral artery or an intracranial artery carried out within 6 weeks prior to date of randomisation
- Planned revascularisation of the contralateral carotid artery or a vertebral artery or an intracranial artery within 6 weeks
- Patients who have a life expectancy of less than 2 years due to a pre-existing condition, e.g. cancer
- Patients intolerant or allergic to all of the medications available for optimised medical therapy

Interventions
Explanation for the choice of comparators (6b)
ECST and NASCET were completed over 20 years ago and since then medical therapy has improved significantly. The widespread use of statins, lower targets for blood pressure control and more effective and promptly started antithrombotic therapy have been shown to lower the incidence of recurrent stroke in prospective registries and trials of stroke prevention [20, 21]. There has been a fall in the proportion of smokers, reduction in baseline cholesterol and blood pressure levels and increased use of dual antiplatelet therapy after stroke or TIA [22, 23]. Subgroup analyses from randomised controlled trials and case-control studies have shown that statins lower the risk of stroke in patients with cerebrovascular disease by about a third and halve the numbers requiring CEA [24–27]. Systematic reviews have consistently shown a reduction in the average rates of ipsilateral stroke in patients with asymptomatic stenosis treated medically to as low as 1% per annum [28, 29]. There is also evidence that OMT with intensive risk factor control and adjustment of medical treatments to target, the annual risk of stroke associated with asymptomatic stenosis might be lowered to 0.6% per annum [30].

Coincidently with the improvement in medical management, there has also been a reduction in the operative risks of CEA since the time of the first trials, with most contemporary databases recording rates of perioperative stroke risk less than 2% in symptomatic patients [31–33]. Given the reductions in perioperative stroke risk and stroke risk with medical therapy alone since ECST, NASCET and ACST, the indications for carotid revascularisation are no longer clear. The data suggest that...
many patients in whom carotid revascularisation is recom-
mended in line with guidelines based on the old tri-
als may be receiving CEA without benefit and with a risk
of harm. It is therefore very relevant to establish whether
these patients should have OMT as the intervention of
first-choice in the future.

Intervention description {11a}
The interventions being compared are immediate revas-
cularisation with OMT versus OMT alone.

Optimised medical therapy (OMT) OMT will be applied
to both treatment groups immediately after randomisa-
tion (if not started beforehand) and includes antihyper-
tensive medication and cholesterol-lowering medication
in combination with a low cholesterol diet, adjusted to
maintain pre-specified targets. The targets are speci-
fied by the local investigator for each patient in line with
European, national or local guidelines. As a guide, we
recommended a target total cholesterol of <4.0mmol/L
(<155 mg/dL) and LDL cholesterol <2.0mmol/L (<77 mg/ 
dL) and treatment to lower blood pressure to a target of
135/85 mmHg for patients aged <80 years and 150/90
mmHg for patients aged >80 years. Antiplatelet therapy is
prescribed according to local guidelines. Anticoagulation
is used as an alternative if indicated. Patients undergo
targeted risk factor modification including smoking ces-
sation and reduction of body weight if relevant.

Revascularisation Patients allocated to revascularisa-
 tion will have CEA (or in selected cases CAS, if consid-
ered preferable to CEA by local investigators) as soon as
possible after randomisation and not later than 2 weeks
for symptomatic patients or 4 weeks for asymptomatic
patients, in addition to OMT. It is anticipated that the
majority of patients allocated to revascularisation will be
reated by endarterectomy. Detailed guidance is available
to centres concerning relative and absolute contraindic-
tions to performing CAS in the trial.

Criteria for discontinuing or modifying allocated
interventions {11b}
Cross-overs will be avoided unless clinically essential.
Patient refusal of the treatment to which they are ran-
donmed will be minimised by careful consent. It is
anticipated that early crossover will primarily occur in
patients randomised to revascularisation in whom con-
traindications to intervention emerge after randomisa-
tion, so that they do not receive early revascularisation.
Patients randomised to OMT alone should only receive
revascularisation of the randomised artery if they have
ipsilateral symptoms after randomisation which are
attributed to the carotid stenosis and are considered
to necessitate revascularisation. Such patients are not
considered cross-overs. Patients requiring revascular-
isation because of new symptoms after allocation to
OMT alone, as well as those requiring revascularisation
of the contralateral, non-randomised carotid artery or
needing a second carotid revascularisation procedure
(e.g. because of symptomatic restenosis) can be re-
treated with whichever method of revascularisation the
local investigator considers most appropriate.

Strategies to improve adherence to interventions {11c}
Success at achieving risk factor control and treatment
targets for OMT is monitored at follow-up. Investiga-
tors, patients and their general practitioner receive
written advice concerning treatment targets. All
patients are requested to schedule follow-up appoint-
ments depending on their availability to prevent redund-
cancy of participants. The research team reminds
the patient regarding their upcoming appointments
through the mail, text or phone call.

Relevant concomitant care permitted or prohibited
during the trial {11d}
Any concomitant care for any other illnesses is allowed
throughout the study.

Provisions for post-trial care {30}
After completion of follow-up, patients will continue
to receive optimised medical therapy according to local
practice.

Outcomes {12}
The primary outcome measure is stroke in any territory
at any time, or periprocedural death attributed to carotid
revascularisation. The primary analyses will examine the
following question: What is the difference in the long-
term survival free of any stroke, or periprocedural death
in patients with atherosclerotic carotid stenosis at lower
risk for stroke after randomisation to a policy of carotid
revascularisation with OMT compared to OMT alone?

The primary outcome measure for the initial MRI-
based analysis of the trial is the combined 2-year rate
of any clinically manifest stroke, new cerebral infarc-
tion on MRI, myocardial infarction or periprocedural death.
Secondary outcome measures include hyperperfu-
sion syndrome, new-onset epileptic seizure, any hospi-
talisation for vascular disease, carotid revascularisation
during follow-up other than that allocated at randomisa-
tion, cranial nerve palsy attributed to revascularisation,
haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay, other adverse events attributed to medical treatment or revascularisation, stenosis progression (defined as recurrent stenosis of the randomised artery after revascularisation, or progression in severity of stenosis in a non-revascularised artery), further revascularisation of the randomised artery after the initial attempt, decline in cognitive function assessed by the Montreal Cognitive Assessment (MoCA) and decline in functional status as assessed by an increase in the modified Rankin score (mRS). In addition, measures will be reported relating to the quality of life and health status, health service use (e.g. length of stay in hospital, surgery, medications) and health service costs.

Imaging protocols

**Brain MRI**

Mandatory MRI sequences include fluid-attenuated inversion recovery (FLAIR), to assess chronic ischaemic brain infarcts and markers of small vessel disease; diffusion-weighted imaging (DWI) to assess acute ischaemic brain lesions; and susceptibility-weighted imaging (SWI) or, if not available, T2*-weighted gradient-echo imaging (GRE), to detect cerebral micro-haemorrhages and other haemorrhagic brain lesions (Table 2). Centres are free to use magnetic field strengths of either 1.5 or 3.0 Tesla but should use the same scanner for each trial patient.

**Carotid plaque imaging**

MRI is far superior to computed tomography (CT) in identifying the different components of a carotid plaque, in particular IPH. Several carotid plaque MRI protocols are summarised in a recent white paper [34]. Centres are given flexibility to choose their preferred plaque imaging protocol according to their local expertise from within a limited number of sequences varying in complexity and performed with or without the use of gadolinium-based contrast medium (Table 2). The basic protocol, which is well suited for demonstrating IPH, requires two sequences: 3D time of flight (TOF) and 3D magnetisation-prepared rapid gradient-echo (MPRAGE) or an equivalent MRI sequence that allows visualisation of IPH. This minimum requirement could be implemented at any centre using a standard head-and-neck coil on a 1.5 or 3.0 Tesla system, although the latter is preferable. The sequences of the basic protocol will allow quantification of stenosis, as well as detection of plaque ulceration, calcification and IPH [34]. Ulcerations will be scored on contrast-enhanced MR angiography, alternatively on 3D TOF, or, if unavailable, any other sequence that allows identification of plaque ulceration. Plaque ulceration is defined as an intimal defect larger than 1 mm in width [35]. IPH is identified as a hyperintense region (compared to the sternocleidomastoid muscle) in the bulk of the plaque on MPRAGE or if unavailable, TOF images or any other sequence that allows identification of IPH [34, 36].

More advanced sequences that have been designed to image plaque burden, the status of the fibrous cap and the size of lipid-rich necrotic core, based on recent expert consensus recommendations, are optional [34]. A thin or ruptured fibrous cap is defined as an interrupted region of signal enhancement adjacent to the lumen on the post-contrast images overlying the lipid-rich necrotic core or full absence of a region with signal enhancement adjacent to the lumen overlying the lipid-rich necrotic core.

### Table 2  MR imaging protocols in ECST-2

| Brain MR imaging | Carotid plaque MR imaging |
|------------------|---------------------------|
| **Required sequences** | **Required sequences** |
| T1-weighted imaging | 3D time of flight (TOF) |
| T2-weighted imaging | 3D magnetisation-prepared rapid gradient-echo (MPRAGE) or an equivalent sequence that allows identification of intraplaque haemorrhage |
| Fluid-attenuated inversion recovery (FLAIR) |  |
| Diffusion-weighted imaging (DWI) | Pre- and post-contrast T1-weighted SPACE/CUBE/VISTA imaging |
| Gradient echo T2*-weighted imaging (or susceptibility-weighted imaging [SWI]) |  |
| **Optional sequences** | **Optional sequences** |
| 3D with contrast | 3D with contrast |
| 2D with contrast | Pre- and post-contrast T1-weighted black blood imaging |
| 3D without contrast | T1-weighted and T2-weighted black blood SPACE/CUBE/VISTA imaging |
| 2D without contrast | Black blood T1-weighted imaging |

* The option is given to use intravenous gadolinium contrast. It is preferred to use 3D imaging however there is an option for 2D imaging

---

[34] Cheng et al. Trials (2022) 23:606

---

[35] IPH is identified as a hyperintense region (compared to the sternocleidomastoid muscle) in the bulk of the plaque on MPRAGE or if unavailable, TOF images or any other sequence that allows identification of IPH [34, 36].

---

[36] More advanced sequences that have been designed to image plaque burden, the status of the fibrous cap and the size of lipid-rich necrotic core, based on recent expert consensus recommendations, are optional [34]. A thin or ruptured fibrous cap is defined as an interrupted region of signal enhancement adjacent to the lumen on the post-contrast images overlying the lipid-rich necrotic core or full absence of a region with signal enhancement adjacent to the lumen overlying the lipid-rich necrotic core.
A quality score is used to indicate the certainty on the score. A lipid-rich necrotic core is identified as an area in the bulk of the plaque that is hyperintense on the T1-weighted black blood MR images, does not enhance on the post-contrast T1-weighted black blood images, and potentially is hypointense in the same region on T2-weighted MR images.

**Duplex ultrasound**

Carotid duplex ultrasound will be performed at baseline and annually to estimate the percentage diameter reduction and grading of stenosis of the carotid artery on the randomised side and on the contralateral side. The degree of stenosis will be determined in the central trial office based on the peak systolic velocities of the common carotid and the internal carotid arteries and the end diastolic velocity of the internal carotid artery, on the basis of predefined, standardised flow velocity criteria, which equate well with the severity of carotid stenosis measured on catheter angiography using the NASCET method [38, 39].

---

**Participant timeline**

Table 3 summarises the timing of baseline and follow-up visits and investigations given in the protocol. Prior to randomisation, the following investigations are required: routine serum investigations, electrocardiogram, imaging of both carotid bifurcations showing the severity of stenosis bilaterally and brain MRI. If MR is contra-indicated or not available within a reasonable time period for any reason, brain CT should be done instead. Baseline data will be collected at randomisation and includes the mRS assessed by using the Rankin Focused Assessment (RFA). Patients also complete the European Quality-of-Life 5 Dimension Questionnaire (EQ-5D) [40] at baseline and the MoCA [41]. Patients are followed up by a neurologist or stroke physician, or a clinician/research practitioner under the close supervision of a neurologist or stroke physician. Required investigations during follow-up include at least annual measurements of the blood pressure and serum cholesterol and an annual carotid duplex ultrasound. Brain MRI is required at the time.

---

**Table 3** Outline of baseline and follow-up appointments including investigations required and target time window

| Visit/follow-up | Investigations | Target time window |
|-----------------|----------------|-------------------|
| Baseline        | Brain MRI     | 14 days in symptomatic stenosis or 28 days in asymptomatic stenosis before or after randomisation, done before any revascularisation procedure |
|                 | Initial carotid imaging | 120 days before randomisation up to the day of randomisation |
|                 | Confirmatory second carotid imaging | 14 days before randomisation up to the day of randomisation |
|                 | Clinical assessment, blood pressure | 14 days before randomisation up to the day of randomisation |
|                 | Baseline blood lipids and glucose, serum troponin levels | 14 days before randomisation up to the day of randomisation |
|                 | ECG MoCA, EQ-5D, RFA | 14 days before randomisation up to the day of randomisation |
| Post-procedure visit in revascularised patients only | Clinical assessment, blood pressure Troponin and ECG | Day of treatment +48 h ±24 h |
| 4–6 weeks post-randomisation | Clinical assessment, blood pressure MoCA, EQ-5D, RFA ECG and troponin in the OMT arm | Day of treatment +30 days ±7 days in revascularised patients |
|                 | Carotid ultrasound in revascularised patients Brain MRI (optional) | Day of treatment +30 days ±7 days |
| 3 months post-randomisation | Telephone follow-up | Day of randomisation +90 days ±14 days |
| 6 months post-randomisation | Clinical assessment, blood pressure EQ-5D, RFA Fasting lipids and glucose | Day of randomisation +180 days ±14 days |
| Annual follow-up | Clinical assessment, blood pressure EQ-5D, RFA Fasting lipids and glucose Carotid ultrasound MoCA and brain MRI at 2 and 5 years | Day of randomisation +X years ±1 month |
| Bi-annual telephone follow-up | Telephone follow-ups between annual follow-ups | Day of randomisation +X years +6 months ±1 month |
of randomisation and at 2 and 5 years after randomisation to determine the rate of the MR-based outcome events, unless contra-indicated. Additional brain MRI is required whenever a suspected stroke or a TIA occurs during the study period to confirm the clinical diagnosis. In patients with contraindications for MRI or if MRI was not available within a reasonable period, brain CT is allowed instead. MRI of the carotid plaque is also done prior to randomisation at centres able to perform the required sequences.

Sample size [14]
We expect a rate of stroke in the OMT arm of approximately 3% at 2 years after randomisation. Silent ischaemic infarcts on MRI seem to occur at twice the frequency of clinically manifest strokes [42, 43]. Thus, we expect about 9% of patients on OMT to experience clinically manifest stroke or have silent new ischaemic infarct on MRI after 2 years of follow-up. In those allocated to revascularisation, we expect a peri-operative risk of stroke of 3% and a subsequent 2-year risk of stroke of 2%. Thus, we expect about 15% of patients in the revascularisation arm to experience clinically manifest stroke or have silent new ischaemic infarct on MRI after 2 years of follow-up.

The rate of clinically manifest periprocedural myocardial infarction (MI) in carotid revascularisation is about 1% [44]. The 2-year risk of non-periprocedural MI is expected to be about 2% using the Framingham model [45] based on the characteristics of patients in the International Carotid Stenting Study (ICSS) [46]. We therefore estimated a total 2-year risk of MI of 3% in patients randomised to revascularisation and 2% in those randomised to OMT. The periprocedural death rate (unrelated to MI or stroke) in ICSS patients undergoing CEA was 0.1%. The rate of the primary outcome event in ECST-2 of clinically manifest stroke, new ischaemic infarct on MRI, MI or periprocedural death at 2 years was therefore estimated at 11% in the OMT arm alone and 18% in the revascularisation arm. Assuming these outcome event rates, 314 patients (157 in each arm) provide 80% power to demonstrate that OMT is non-inferior to OMT plus revascularisation with a non-inferiority margin of 4%. Allowing for a dropout of 15% of patients missing their 2-year MRI, we plan to recruit 360 patients for the MRI-based analysis.

We originally calculated a sample size of 2000 patients for the full ECST-2 trial, details of which can be found in the trial protocol. The sample size calculation for the continuation or re-launch of the study will be based on the outcome rates determined in the initial analysis.

Recruitment [15]
The strategies adopted to achieve adequate participant enrolment included consultation with collaborators at investigators’ meetings and regular communication with investigators via a regular newsletter. Centres are also provided with on-site or remote training at set up of the centre or when a new investigator joined the team. Centres are provided with individualised feedback on the progress with recruitment and reminders concerning patient follow-up and missing data. All investigators have email access to a trial manager based in the central office and to the chief investigator, who answers queries promptly, including those related to participant enrolment.

ECST-2 allows centres to use their normal clinical practice to identify patients with carotid stenosis. The NASCET criteria were specified for measurement of the degree of carotid stenosis [38, 47]. The imaging modality to grade carotid stenosis and assess suitability for revascularisation is not specified, but confirmation using a second imaging modality before randomisation is required.

Assignment of interventions: allocation

Sequence generation [16a]
A randomisation tool is provided to investigators on a secure password-protected website (www.sealedenvelope.com). Patients are randomly allocated in a 1:1 ratio to be treated either by (1) immediate carotid revascularisation plus OMT or (2) by OMT alone.

Concealment mechanism [16b]
Allocation is balanced by minimisation on the following factors: recruitment centre, planned method of revascularisation (endarterectomy, stenting, angioplasty) and risk group (asymptomatic with stenosis ≥ 70%, asymptomatic with stenosis < 70%, and CAR score in symptomatic stenosis). The minimisation incorporates a random component so that the treatment group that minimises imbalance is chosen with probability of 0.85. Separate randomisation lists are maintained according to whether endarterectomy or stenting was the pre-specified treatment.

Implementation [16c]
A study number is assigned at the point of enrolment after the patient signed and dated the informed consent. The investigator or research team assigns the patient to the intervention according to the intervention allocated to the patient.

Assignment of interventions: blinding

Who will be blinded [17a]
Because of the nature of the interventions being compared it is not practical to blind patients or clinicians to
the treatment allocated. However, all follow-ups will be performed by neurologists or stroke physicians or staff under their close supervision rather than the surgeons or interventionists performing revascularisation. The central office staff, chief investigator and Steering Committee will all remain blinded to the cumulative event rate in the two arms until the interim analysis is complete. Follow-up MRI and CT scans will be analysed blind to treatment received, providing a non-biased comparison of outcome in the two groups. Major outcomes will be adjudicated by an adjudication committee who is blinded to the allocated treatment.

Procedure for unblinding if needed (17b)
The central office staff, chief investigator and Steering Committee will remain blinded until the completion of the first analysis of the trial results, unless advised to the contrary by the Data Monitoring Committee.

Data collection and management

Plans for assessment and collection of outcomes (18a)
Data will be collected and captured using an electronic case record form on Sealed Envelope (www.sealedenvelope.com). All 30-day post-procedural complications after revascularisation and other outcome events will be reported in detail to the central office. At each visit, levels of disability will be assessed using a structured interview to determine the mRS and any outcome events notified to the Central Office. In patients with suspected or confirmed TIA or stroke during follow-up, an additional MRI brain scan will be done to confirm the diagnosis (unless contraindicated, when a CT will be done instead) together with an ultrasound or other re-examination of the carotid arteries. Copies of the images and reports will be returned to the trial office to assist with central adjudication and analysis.

Plans to promote participant retention and complete follow-up (18b)
Treatment refusals and cross-overs are minimised by careful informed consent. The effectiveness of the OMT regime will be monitored at follow-up; GPs are asked to monitor patients’ blood pressure and cholesterol at regular intervals and these data will be collected at the scheduled trial follow-up visits.

Data management (19)
Digital copies of the MRI or CT scans and the imaging of the carotid bifurcation will be sent to the Central Trial Office for central analysis together with copies of ECGs and the written reports of the imaging studies. Where more than one imaging modality has been used to image the brain or carotid bifurcations, copies of all the investigations will be sent to the Central Office. All brain and carotid images are stored on a central secure database and will be analysed by expert trial neuroradiologists and/or trained observers to refine prediction of risk and benefit of carotid revascularisation.

Confidentiality (27)
All data obtained in this trial is kept and handled in a confidential manner in accordance with applicable laws and regulations. Sealed envelope servers follow the latest cipher suites and security guidelines and all web-based traffic in transit is encrypted.

Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use (33)
Blood samples for genetic analysis are collected and stored in a secure location for future analysis.

Statistical methods

Statistical methods for primary and secondary outcomes (20a)
The primary analysis will be by intention-to-treat; i.e. patients will be analysed by their randomly allocated group despite what treatment they actually receive. A per-protocol analysis will be performed as an indicator of the actual treatment effect, excluding (i) patients randomised in the OMT group who undergo revascularisation within 6 weeks of randomisation without prior symptoms, as well as (ii) patients randomised in the revascularisation group who do not undergo revascularisation within 6 weeks of randomisation.

Interim analyses (21b)
An initial analysis will be performed to assess the safety of the treatment policies and inform the design and sample size calculations for the full trial, with the combined 2-year outcome of any stroke, new cerebral infarct on MRI, MI or periprocedural death. During the period of recruitment to the study, interim analyses of mortality and of any other information that is available on major endpoints (including serious adverse events believed to be due to treatment) will be provided, in strict confidence, to the Data Monitoring Committee by the trial statistician, along with any other analyses that the Committee may request. In the light of these analyses, the Data Monitoring Committee will advise the chairman of the Steering Committee if, in their view, the randomised comparisons in ECST-2 have provided both (i) “proof beyond reasonable doubt” that for all, or for some, specific types of patients, one particular treatment is clearly indicated or clearly contraindicated in terms
of a net difference in outcome, and (ii) evidence that might reasonably be expected to materially influence patient management. Appropriate criteria of proof beyond reasonable doubt cannot be specified precisely, but a difference of at least three standard deviations in an interim analysis of a major endpoint may be needed to justify halting, or modifying, the study prematurely.

**Methods for additional analyses (e.g. subgroup analyses)**

Subgroup analyses will examine the influence of individual risk factors for outcome events and potential modifiers of treatment effect. Subgroups of particular interest will be age (dichotomised at the mean and as a continuous variable), sex, symptomatic versus asymptomatic carotid stenosis, CAR score, diabetes, hypertension, severity of stenosis, contralateral stenosis or occlusion, type of most recent event, multiple symptoms, centre recruitment and time from event to revascularisation. In addition, subgroup analyses according to the presence or absence of IPH will be done. The results will also be analysed according to adherence to OMT targets.

**Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data**

Patients who stop attending regular follow-up visits without occurrence of an outcome event will be censored at the time of their last visit. Censoring is non-informative. The trial management team strives for a high level of data completeness. Statistical imputation of missing data is not foreseen.

**Oversight and monitoring**

**Composition of the coordinating centre and trial steering committee**

The study will be organised on behalf of the collaborators by the UCL Queen Square Institute of Neurology in London. The office will be responsible for protocol design, data collection and management and analysis of the results in consultation with the Steering and Data Monitoring Committees. The Steering Committee consists of the chief investigator and individuals participating in and independent of the trial with experience in vascular neurology, cardiovascular disease, vascular surgery, vascular radiology, interventional neuroradiology, health economics, clinical trials and statistics, together with patient and carer representatives. Individual Country Coordinators from the most active centres will be represented on the committee. The Steering Committee will have an independent Chairman and will oversee the overall management of the trial.

**Composition of the data monitoring committee, its role and reporting structure**

The safety aspects of the trial will be overseen by an independent Data Monitoring Committee with expertise in neurology, clinical trials, medical statistics, vascular surgery and clinical pharmacology.

**Adverse event reporting and harms**

Outcome events will be documented in detail by the investigating centre. Patients suffering from a stroke should have an MRI brain scan as soon as possible after the event (or CT if contraindicated). An electronic copy of this will be submitted together with a report of the event. For MI, documentation of changes in cardiac biomarkers and copies of ECG recordings should be returned to the trial office. The event report will include copies of discharge summaries, death certificates and post-mortem results if relevant. Deaths of UK patients will be tracked by flagging patients against the UK Registry of Births and Deaths. Disability after stroke and cranial nerve palsy will be assessed 30 days and 6 months after treatment or onset, using the mRS. Duration of symptoms will be recorded and outcome events will be classified as disabling if the mRS is 3 or more. Reports of outcome events will be censored after receipt at the central office to remove information concerning treatment allocation as far as practical and then sent for adjudication as soon as sufficient information concerning the event has been received. Major outcome events will be adjudicated by two neurologists or cardiologists, depending on the reported event, at least one of whom will be independent of the trial. If the two physicians differ significantly in the classification of the event, the data will be sent to another independent adjudicator for their views. Major conflicts will be resolved by consensus or a majority view if consensus is not achieved. Additional information may be requested at any time by the central office or an adjudicating physician.

If the local investigator or other member of the team, at a trial centre, has concern about the outcome of their trial procedures, they should inform the trial office, which will organise a blinded assessment of the relevant outcome events. This will be submitted by the central office to the chairman of the Data Monitoring Committee who may recommend further action, such as suspending randomisation at the centre. Similarly, the database manager at the trial office will monitor outcome events and if there are two consecutive deaths or three consecutive major events at a single centre within 30 days of treatment in the same arm of the study, then assessment of the events will be triggered. A cumulative major event or death rate of 10% or more over 20 cases would also trigger careful assessment of the relevant outcome events.
Frequency and plans for auditing trial conduct (23)
The progress of the study is assessed at regular intervals determined by the Data Monitoring Committee.

Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) (25)
The Central Trial Office consults with the collaborators at investigators’ meetings and at other times as necessary. Communication with investigators also takes place via a regular newsletter and the trial website.

Access to trial data (29)
Non-identifiable data and materials from the final trial dataset will be freely available to any suitable individual or organisation in response to a reasonable and well-motivated request addressed to the chief investigator. Research outputs arising from any analysis of trial data should appropriately acknowledge the funding and support received for the research.

Dissemination plans (31a)
The main results of the trial will be submitted for presentation at relevant scientific conferences. Publications resulting from the analysis of the trial will be disseminated through peer-reviewed publications. Key publications will be made available to the public through open-access publication.

Authorship eligibility (31b)
A writing committee appointed by the chief investigator will prepare the main manuscripts on behalf of the trial investigators. The writing committee will include representatives from the trial office staff, trial steering committee and the most active recruiting centres. Members of the writing committee will be expected to conform with the requirements for authorship and contribution published by the International Committee of Medical Journal Editors.

Plans to give access to the full protocol, participant-level data and statistical code (31c)
The full trial protocol (version 3.1) is available to download from the trial website (www.ecst2.com). It is not planned that the participant-level dataset and statistical code will be made publicly available, except as outlined under the heading ‘Access to trial data’ above.

Discussion
The objective of ECST-2 is to test the hypothesis that patients with carotid stenosis ≥50% associated with a low to intermediate risk of stroke will not benefit from additional carotid revascularisation when treated with optimised medical therapy, because vascularisation surgery will cause more periprocedural vascular events than are prevented by removal of the plaque. ECST-2 is designed to closely reflect current medical practice so that the results of the trial are applicable to everyday medicine.

ECST-2 differs from previous and ongoing trials of carotid stenosis in several important aspects. Firstly, to select patients for the trial, rather than selecting patients on the basis of symptom status as in previous carotid trials, ECST-2 uses an individualised risk assessment tool, the Carotid Artery Risk (CAR) score, which is derived from a validated model based on several clinical variables. It is notable that many patients with symptomatic stenosis have a low predicted risk of future stroke similar to that of patients with asymptomatic stenosis. Therefore, ECST-2 includes both patients with lower risk symptomatic stenosis and those with asymptomatic stenosis, viewing risk as a spectrum for which symptomatic status contributes only a part. Secondly, ECST-2 defined OMT using international guidelines and encouraged achievement of these guideline-based treatment targets, unlike previous carotid trials which did not define best medical treatment. Thirdly, ECST-2 routinely uses MRI as an additional, sensitive and objective tool that can be analysed blind to treatment to assess ischaemic or haemorrhagic brain injury at enrolment and occurring as a consequence of revascularisation or the failure of medical treatment during follow-up. Finally, the trial also represents a unique opportunity to investigate whether the findings on MRI of the carotid plaque help select patients who benefit from revascularisation. Plaque MRI has been assessed in non-randomised prospective carotid disease studies, which suggest that certain features including IPH, visualised using appropriate MR sequences, predict a high rate of future ischaemic stroke on medical therapy alone, independent of the degree of stenosis [18]. The presence of IPH correlates with a higher risk of ipsilateral stroke in patients with symptomatic stenosis with an unadjusted hazard ratio of 10.2 (95% CI 4.6–22.5) [18, 48, 49]. However, these studies have not established whether IPH also predicts a higher rate of perioperative stroke in patients receiving early revascularisation, nor whether patients with IPH, who otherwise appear to have a low risk of recurrent stroke and randomised to OMT only, benefit from carotid revascularisation. ECST-2 provides a unique opportunity to answer these questions.

We recognise that event rates might be different to those predicted and therefore the analysis of the trial might not yield sufficient evidence to prove or refute our hypothesis. Thus, to determine the optimum
management of low-risk patients with carotid stenosis, the results of further trials will be needed, including those of CREST-2 (Second Carotid Revascularization Endarterectomy versus Stenting Trial), SPACE-2 (Stent Protected Angioplasty versus Carotid Endarterectomy), and ACTRIS (Endarterectomy Combined With OMT vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-Than-Average Risk of Ipsilateral Stroke, https://clinicaltrials.gov/ct2/show/NCT02841098) [50, 51].

Current guidelines are based on the results of randomised clinical trials performed several decades ago, despite remarkable falls in rates of stroke associated with carotid stenosis related to improvements in medical and surgical practice. The results of ECST-2 and other ongoing trials will allow the guidelines to be updated with more current figures for surgical complication rates and risks on OMT alone.

A further main aim of ECST-2 is to determine whether the use of the CAR score, baseline brain MRI and baseline plaque MRI can be used to improve risk prediction in individual patients. We anticipate that the results of ECST-2 together with the results of other studies of brain and plaque imaging will usher in an era of personalised stroke prevention for patients with atherosclerotic carotid artery stenosis in which treatment (OMT with or without revascularisation) is recommended for patients based on individualised assessment of their future stroke risk incorporating imaging-based analysis (Table 3).

**Trial status**
ECST-2 was registered as an international clinical trial in the ISRCTN registry in July 2012 (ISRCTN97744893). It was originally conceived that an initial analysis would be performed, based on the MRI analysis of cerebral infarction and haemorrhage, as described above, to inform the design and sample size of a continuation of the trial, with an anticipated final sample size of 2000 required to perform an analysis based on clinically evident events only. However, the technology available to assess risk was rapidly advancing with the development of MRI of the carotid plaque and the demonstration that IPH appeared to be a powerful predictor of stroke outcome in lower-risk patients treated medically. The steering committee therefore decided to suspend randomisation in ECST-2 in October 2020 after recruiting sufficient patients to conduct both the planned brain imaging-based analysis of outcome events and the plaque MRI analysis. The COVID-19 pandemic in 2020 and 2021 impacted on the follow-up of the study population by delaying visits at some centres, but currently, follow-up is planned to continue to allow a 5-year follow-up of the last enrolled patients. A decision will be made on the design for the re-launch of randomisation in ECST-2 with a similar or altered design when the results of the initial analysis are available. The steering committee was also cognisant that new funding would be required to re-launch recruitment in the trial.

**Abbreviations**
ACST: Asymptomatic Carotid Surgery Trial; CAR: Carotid Artery Risk; CAS: Carotid artery stenting; CEA: Carotid endarterectomy; CREST-2: Second Carotid Revascularization Endarterectomy versus Stenting Trial; CT: Computerised tomography; DWI: Diffusion-weighted imaging; ECST: European Carotid Surgery Trial; ECST-2: Second European Carotid Surgery Trial; EQ-SD: European Quality-of-Life 5 Dimension Questionnaire; FLAIR: Fluid-attenuated inversion recovery; GRE: Gradient-echo imaging; ICSS: International Carotid Stenting Study; IPH: Intra-plaque haemorrhage; MI: Myocardial infarction; MoCA: Montreal Cognitive Assessment; MPRAGE: Magnetisation-prepared rapid gradient-echo; MRI: Magnetic resonance imaging; mRS: Modified Rankin score; NASCET: North American Carotid Endarterectomy Trial; OMT: Optimised medical therapy; RFA: Rankin Focused Assessment; SWI: Susceptibility-weighted imaging; TIA: Transient ischaemic attack; TOF: Time of flight; UCL: University College London.

**Acknowledgements**
Not applicable.

**Authors’ contributions**
MMB, LHB, and PJN conceived the publication and made major contributions to the wording. SFC contributed to drafting the manuscript and finalising the manuscript. All authors provided critical revision of the paper and read and approved the final manuscript.

**Funding [4]**
This paper presents independent research initially funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RPB) Programme (Grant Reference Number PB-PG-0609-19216). The study continued with an additional project grant from the Stroke Association (Grant Reference Number TSA 2013/04) to allow recruitment of the sample size of 320 patients with MR brain imaging required for the initial analysis. Funding was subsequently obtained from the Swiss National Science Foundation (grant number 32003B-150688) to support additional MR plaque imaging, and for a cost-effectiveness analysis by the Netherlands Organisation of Scientific Research (ZONMW; project nr. 843004107). Part of the work was undertaken at University College London and University College London Hospitals NHS Foundation Trust, which receives a proportion of funding from the UK Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme. The views expressed in the paper are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The funding bodies have no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

**Declarations**

**Ethics approval and consent to participate [24]**
The trial received ethical and NHS approval from the National Research Ethics Service in the UK after review by the NRES Committee East of England, Cambridge Central (ref. 11/EE/0347). Individual centres in the UK are required to have local Trust approval before recruiting patients. Outside of the UK, ethics approval is required according to local arrangements.

**Consent for publication [32]**
Not applicable.

**Competing interests [28]**
The authors declare that they have no competing interests.
Author details
1 Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK. 2 Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 3 Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK. 4 Faculty of Health and Medical Sciences, Surgery, University of Western Australia, Perth, Australia. 5 Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK. 6 Lyskolm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK. 7 Comprehensive Stroke Service, University College London Hospitals NHS Foundation Trust, London, UK. 8 Department of Radiology and Nuclear Medicine, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands. 9 Department of Vascular Surgery, University Medical Center, Utrecht, The Netherlands. 10 Radiology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy. 11 Department of Neurology, University Hospital Basel, Basel, Switzerland. 12 Department of Clinical Research, University of Basel, Basel, Switzerland. 13 Research Department, Reha Rheinfelden, Rheinfelden, Switzerland.

Received: 25 February 2022 Accepted: 26 May 2022

Published online: 27 July 2022

References
1. Cheng SF, Brown MM, Simister RJ, Richards T. Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke. Br J Surg. 2019;106(7):872–7.
2. European Carotid Surgery Trialists’ Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European carotid surgery trial (ECST). Lancet. 1998;351(9113):1379–87.
3. Barnett HJ, Taylor DW, Elasizmiz M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. New Engl J Med. 1998;339(20):1415–25.
4. Rothwell PM, Mehta Z, Howard G, Gutnikov SA, Warlow CP. From subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365(9455):256–65.
5. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists’ Collaborative Group. Lancet. 1999;353(9170):2105–10.
6. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363(9420):1491–502.
7. Halliday A, Hassan M, Hayter E, Kong XL, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet. 2010;376(9746):1074–84.
8. Walker MD, Marler JR, Goldstein M, Grady PA, Toole JF, Baker WH. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273(18):1421–8.
9. Bonati LH, Lyer P, Edler J, Featherstone R, Brown MM. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev. 2012;9:CD00515.
10. Carotid Stenting Trialists C, Bonati LH, Dobson J, Algra A, Branchereau A, Chatellerie G, et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet. 2010;376(9746):1062–73.
11. Howard G, Roubin GS, Jansen O, Hendrikse J, Halliday A, Fraedrich G, et al. Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Lancet. 2016;387(10023):1305–11.
12. Vernooy MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, et al. Incidental findings on brain MRI in the general population. New Engl J Med. 2007;357(18):1821–8.
13. Cheung NP, Masley T, Islam A, Kawasaki R, Sharrett AR, Klein R, et al. Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain. 2010;133:1987–93.
14. Schnauferel G, Grossek H, Pilgram SM, Kastrup A. New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. Stroke. 2008;39(6):1911–9.
15. Canyigit M, Arat A, Cil BE, Turkbey B, Saatci I, Cekirge S, et al. Distal embolization after stenting of the vertebral artery: diffusion-weighted magnetic resonance imaging findings. Cardiovasc Intervent Radiol. 2007;30(2):189–93.
16. Bonati LH, Jongen LM, Haller S, Flach HZ, Dobson J, Niederkoenig PJ, et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a study of the International Carotid Stenting Study (ICSS). Lancet Neurol. 2010;9(4):353–62.
17. Fu HJ, Mok V, Lam W, Wong A, Chu W, Xiong Y, et al. Effects of statins on progression of subclinical brain infarct. Cerebrovasc Dis. 2010;30(1):51–6.
18. Schindler A, Schinner R, Altat N, Hosseini AA, Simpson RJ, Esposito-Bauer L, et al. Prediction of stroke risk by detection of hemorrhage in carotid plaques: meta-analysis of individual patient data. JACC Cardiovasc Imaging. 2019;12(3 Pt 1):395–406.
19. Rothwell PM, Gurtikov SA, Warlow CP. For the ECST. Re-analysis of the final results of the European Carotid Surgery Trial. Stroke. 2003;34:514–23.
20. Amarenco P, Lavalette PC, Tavares LM, Labreuche J, Albers GW, Abboud H, et al. Five-year risk of stroke after TIAs or minor ischemic stroke. New Engl J Med. 2018;379(23):2182–90.
21. Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res. 2017;120(2):366–80.
22. Biasco L, Montrasio G, Moccetti M, Pedrazzini G. Current trends in dual antplatelet therapy: a 2017 update. Cardiovasc Med. 2017;20(708):169–75.
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,336 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9236):7–22.
24. Sillehun H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39(12):3297–302.
25. Milionis HJ, Giannopoulous S, Kosmidou M, Panoulaev V, Manois E, Kyrtis AP, et al. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology. 2009;72(21):1816–22.
26. Amarenco P, Rogousslacky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med. 2006;355(6):549–59.
27. Naylor AR. Time to rethink management strategies in asymptomatic carotid artery disease. Nat Rev Cardiol. 2011;9(2):116–24.
28. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review. Eur J Vasc Endovasc Surg. 2009;37(5):504–11.
29. Shah Z, Masoomi R, Thapa R, Wani M, Chen J, Dawn B, et al. Optimal medical management reduces risk of disease progression and ischemic events in asymptomatic carotid stenosis patients: a long-term follow-up study. Cerebrovasc Dis. 2017;44(3-4):150–9.
30. Rerkasem K, Rothwell PM. Temporal trends in the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis: an updated systematic review. Eur J Vasc Endovasc Surg. 2009;37(5):504–11.
31. Müller MD, von Fellen S, Algra A, Becquemin JP, Bulbulia R, Calvet D, et al. Secular trends in procedural stroke or death risks of stenting versus endarterectomy for symptomatic carotid stenosis: a pooled analysis of randomized trials. Circ Cardiovasc Interv. 2019;12(8):e007870.
32. The Royal College of Surgeons of England, Vascular Society of Great Britain and Ireland, British Society of Interventional Radiology: National Vascular Registry: 2021 annual report: Vascular Services Quality Improvement Programme; 2021. https://www.vsqip.org.uk/reports/2021-annual-report. Accessed 1 Apr 2022.
33. Cheng SF, Brown MM. Contemporary medical therapies of atherosclerotic carotid artery disease. Semin Vasc Surg. 2017;30(1):8–16.
34. Saibali, Yuan C, Hatsuken T, Balu N, Qiao Y, DeMarco K, et al. Carotid artery wall imaging: perspective and guidelines from the ASNR Vessel Wall Imaging Study Group and Expert Consensus Recommendations of the American Society of Neuroradiology: AJNR Am J Neuroradiol. 2018;39(2):E9–E31.
35. Sitzer M, Muller W, Siebler M, Hort W, Kniemeyer HW, Jancke L, et al. Plaque ulceration and lumen thrombus are the main sources of cerebral microemboli in high-grade internal carotid artery stenosis. Stroke. 1995;26(7):1231–3.

36. Kwee RM, van Engelshoven JMA, Mess WH, ter Berg JWM, Schreuder FHBM, Franke CL, et al. Reproducibility of fibrous cap status assessment of carotid artery plaques by contrast-enhanced MRI. Stroke. 2009;40(9):3017–21.

37. Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation. 2001;104(17):2051–6.

38. North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke. 1991;22:711–20.

39. McCabe DJ, Pereira AC, Clifton A, Bland JM, Brown MM. Restenosis after carotid angioplasty, stenting, or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS). Stroke. 2005;36:281–6.

40. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.

41. Pendlebury ST, Cuthbertson FC, Welch SJ, Mehta Z, Rothwell PM. Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke. 2010;41(6):1290–3.

42. Coutts SB, Hill MD, Simon JE, Sohn CH, Scott JN, Demchuk AM, et al. Silent ischemia in minor stroke and TIA patients identified on MR imaging. Neurology. 2005;65(4):513–7.

43. Kang DW, Lattimore SJ, Latour LL, Warach S. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol. 2006;63(12):1730–3.

44. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM, Brooks W, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. New Engl J Med. 2010;363(1):11–23.

45. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.

46. Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB, de Borst GJ, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet. 2010;375(9719):985–97.

47. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New Engl J Med. 1991;325:445–53.

48. Saam T, Hetterich H, Hoffmann V, Yuan C, Dickhans M, Poppert H, et al. Meta-analysis and systematic review of the predictive value of carotid plaque hemorrhage on cerebrovascular events by magnetic resonance imaging. J Am Coll Cardiol. 2013;62(12):1081–91.

49. Saba L, Saam T, Jäger HR, Yuan C, Hatsukami TS, Saloner D, et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications. Lancet Neurol. 2019;18(6):559–72.

50. Mott M, Koroshetz W, Wright CB. CREST-2: identifying the best method of stroke prevention for carotid artery stenosis. National Institute of Neurological Disorders and Stroke organizational update. Stroke. 2017;48(S):e130–1.

51. Reiff FT, Eckstein HH, Mansmann U, Jansen O, Fraedrich G, Mudra H, et al. Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: one-year interim results of SPACE-2. Int J Stroke. 2020;15(6):638–49.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.